BioCentury
ARTICLE | Clinical News

Leap zeroes in on subgroup for DKN-01, Keytruda combo

August 6, 2019 10:58 PM UTC

Shares of Leap tumbled Tuesday as investors digested updated data from the Phase I trial of DKN-01 that showed a lower response than reported in March for the mAb in combination with Keytruda for advanced gastroesophageal junction and gastric cancer. But the company is optimistic that the combination could provide a benefit for a biomarker-defined group of patients with poor prognosis.

Leap Therapeutics Inc. (NASDAQ:LPTX) finished Tuesday off $0.31 (15%) to $1.77 for a market cap of $41 million, erasing its gains of $0.40 (22%) to $2.25 on March 15 on earlier data...

BCIQ Company Profiles

Leap Therapeutics Inc.